Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Tryptamine

or [[:Category:Loop_diuretics|Loop diuretic]]

Use the filters below to narrow your results.

Codeine (2)

None (31) · (multiple, generic dominant) (1) · Bumex (1) · Darvon (1) · Demadex, Soaanz (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Lasix (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1)

None (2) · 5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent mu-opioid receptor agonist (3) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1)

None (43) · 0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) · 10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) · 20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (43) · 0.5, 1, 2 mg tablets; 0.25 mg/mL IV (1) · 20, 40, 80 mg tablets; 10 mg/mL oral solution; 10 mg/mL IV (1) · 5, 10, 20, 100 mg tablets; 10 mg/mL IV (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (43) · 200 mg/d typical practical ceiling (1) · 360 mg/day (1) · 600 mg/d typical practical ceiling in heart failure (1) · ~10 mg/d typical (1)

None (43) · IM (2) · IV (3) · Oral (3) · PO (only formulation marketed in the US). (1)

None (43) · 30–60 min (PO) (1) · IV: 5 minutes; PO: 30-60 minutes (1) · PO 1 hour; IV 10 minutes (1) · PO 30-60 minutes; IV minutes (1)

None (43) · 4-6 hours (1) · 4–6 hours (1) · 6-8 hours (1) · IV: ~2 hours; PO: 6-8 hours (1)

None (43) · 1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' (1) · 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' (1) · 2.5–3 hours (1) · 3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"' (1)

None (43) · ~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) · ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' (1)

None (43) · Avoid where possible; can reduce uteroplacental perfusion and produce neonatal electrolyte disturbance. Reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (43) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (3)